The invention relates to the field of organic chemistry and pharmacy and provides a novel compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate, a method for treating and preventing functional gastrointestinal disorders, which comprises administering an effective amount of compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxy benzoate 4-methyl-2H-chromen-2-on-7-yl sulphate to a patient in need thereof, a pharmaceutical composition based on compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate, a drug comprising compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate, and a finished dosage form comprising compound [L-(dimethylamino)-2-phenybutyl ]-3,4,5 -trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate. The invention further relates to the use of compound [2-(dimethylamino) phenylbutyl]-3,4,5-trimethoxy benzoate 4-methyl-2H-chromen-2-on-7-yl sulphate for treating and preventing functional gastrointestinal disorders.

The invention relates to the field of organic chemistry and pharmacy and provides a novel compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate, a method for treating and preventing functional gastrointestinal disorders, which comprises administering an effective amount of compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxy benzoate 4-methyl-2H-chromen-2-on-7-yl sulphate to a patient in need thereof, a pharmaceutical composition based on compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate, a drug comprising compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate, and a finished dosage form comprising compound [L-(dimethylamino)-2-phenybutyl ]-3,4,5 -trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate. The invention further relates to the use of compound [2-(dimethylamino) phenylbutyl]-3,4,5-trimethoxy benzoate 4-methyl-2H-chromen-2-on-7-yl sulphate for treating and preventing functional gastrointestinal disorders.

The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (I).

##STR00001##

The present invention relates to a series of novel polymerizable compounds based on 3-ketocoumarins, which are useful as photoinitiators and sensitizers, to compositions comprising said compounds and to a process for photopolymerizing comprising them. ##STR00001##

The present invention relates to a series of novel polymerizable compounds based on 3-ketocoumarins, which are useful as photoinitiators and sensitizers, to compositions comprising said compounds and to a process for photopolymerizing comprising them. ##STR00001##

An embodiment provides a method for measuring mercury in a solution, including: preparing a thiocarbamate-based indicator; introducing the thiocarbamate-based indicator to a solution, wherein the solution contains an amount of mercury and the introducing causes a change in fluorescence of the solution; and measuring the amount of mercury in the solution by measuring a change in intensity of the fluorescence. Other aspects are described and claimed.

An embodiment provides a method for measuring total chlorine in a solution, including: preparing a thiocarbamate indicator; introducing the thiocarbamate indicator to a solution, wherein the solution contains an amount of monochloramine; adding an additive to the solution, wherein the additive accelerates the reaction rate between the thiocarbamate indicator and monochloramine and causes a change in fluorescence of the solution; and measuring the amount of monochloramine in the solution by measuring an intensity of the fluorescence. Other aspects are described and claimed.

The invention pertains to a functionalizable and enzyme-activatable fluorescent probe and methods for monitoring the activity of amine oxidases. Amine oxidases catalyze the oxidative deamination, e.g. of the ε-amine of a lysine to an aldehyde which in turn can form covalent bonds with neighboring side chains, e.g. in the context of collagen cross-linking. Amine oxidase activity can be correlated with collagen-associated diseases including pulmonary and hepatic fibrosis, cardiomyopathy and tumor metastasis.

The invention pertains to a functionalizable and enzyme-activatable fluorescent probe and methods for monitoring the activity of amine oxidases. Amine oxidases catalyze the oxidative deamination, e.g. of the ε-amine of a lysine to an aldehyde which in turn can form covalent bonds with neighboring side chains, e.g. in the context of collagen cross-linking. Amine oxidase activity can be correlated with collagen-associated diseases including pulmonary and hepatic fibrosis, cardiomyopathy and tumor metastasis.

Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.

##STR00001##